MEDIPOST announced on the 23rd that it has obtained a Chinese patent for the method of culturing mesenchymal stem cells which can enhance the efficacy of stem cells.
The patent entitled “Method for culturing mesenchymal stem cells according to the cell size” is a method that can be used for culturing mesenchymal stem cells with a high therapeutic efficacy by controlling the size and culture environment of the cells.
MEDIPOST plans to apply the patent to the next-generation mesenchymal stem cell manufacturing platform to produce a highly efficient therapeutic cell products.
MEDIPOST has acquired the patents of similar technologies in Korea, Japan, Australia, and the United States, and is developing the next-generation pipeline of products through SMUP-Cell platform technology with highly-efficient stem cell culture process which utilizes these patented technologies.
The research work led to the patents has been supported by the Ministry of Health and Welfare for five years since 2012, through the Stem Cells and Regenerative Medicine Consortium Project Grant.